Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma
Publisher's Note: There is an Inside Blood Commentary on this article in this issue.
Gespeichert in:
| Veröffentlicht in: | Blood 2017-09, Vol.130 (11), p.1375-1377 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1377 |
|---|---|
| container_issue | 11 |
| container_start_page | 1375 |
| container_title | Blood |
| container_volume | 130 |
| creator | Connors, Joseph M. Ansell, Stephen M. Fanale, Michelle Park, Steven I. Younes, Anas |
| description | Publisher's Note:
There is an
Inside
Blood
Commentary
on this article in this issue. |
| doi_str_mv | 10.1182/blood-2017-05-784678 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5766843</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497120328779</els_id><sourcerecordid>1922508575</sourcerecordid><originalsourceid>FETCH-LOGICAL-c463t-b8cfc34287071b560ed781c039b0bfa0ab3e30ca2a672bd2e1049e83aea42a913</originalsourceid><addsrcrecordid>eNp9UU1v1DAUtBCILoV_gJCPXAzPdhJnL0hLSylSJS7A1fLHy64hiRc7Sdl_j5ctBS6c5vDezHszQ8hzDq84b8Vr28fomQCuGNRMtVWj2gdkxWvRMgABD8kKABpWrRU_I09y_grAKynqx-RMtEpKKeSKpKuwIDugSbSLfR9v2bynsaM24TjNP8JgLF3QxymM1MXBhhE9vQ3Tjm7efrmkMdFNga6g8YsZHXqWJ7NF6nqTc3Cmp9fRb78Ven8Y9rs4mKfkUWf6jM_u8Jx8vnr36eKa3Xx8_-Fic8Nc1ciJ2dZ1TlblVVDc1g2gVy13INcWbGfAWIkSnBGmUcJ6gRyqNbbSoKmEWXN5Tt6cdPezHdC7YiiZXu9TMZUOOpqg_52MYae3cdG1apq2kkXg5Z1Ait9nzJMeQnbY92bEOGfN10LU0NaqLqvVadWlmHPC7v4MB32sS_-qSx_r0lDrU12F9uLvF-9Jv_v54wFLUEvApLMLeIw5JHST9jH8_8JPZY2pKA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1922508575</pqid></control><display><type>article</type><title>Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Connors, Joseph M. ; Ansell, Stephen M. ; Fanale, Michelle ; Park, Steven I. ; Younes, Anas</creator><creatorcontrib>Connors, Joseph M. ; Ansell, Stephen M. ; Fanale, Michelle ; Park, Steven I. ; Younes, Anas</creatorcontrib><description>Publisher's Note:
There is an
Inside
Blood
Commentary
on this article in this issue.</description><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood-2017-05-784678</identifier><identifier>PMID: 28733323</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject><![CDATA[Adolescent ; Adult ; Antineoplastic Agents, Immunological - administration & dosage ; Antineoplastic Agents, Immunological - adverse effects ; Antineoplastic Agents, Immunological - pharmacology ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Bleomycin - administration & dosage ; Bleomycin - adverse effects ; Brentuximab Vedotin ; Dacarbazine - administration & dosage ; Disease-Free Survival ; Doxorubicin - administration & dosage ; Drug Interactions ; Female ; Follow-Up Studies ; Hodgkin Disease - drug therapy ; Humans ; Immunoconjugates - administration & dosage ; Immunoconjugates - adverse effects ; Immunoconjugates - pharmacology ; Kaplan-Meier Estimate ; Letter to ; Lung Diseases - chemically induced ; Male ; Middle Aged ; Molecular Targeted Therapy ; Remission Induction ; Treatment Outcome ; Vinblastine - administration & dosage ; Young Adult]]></subject><ispartof>Blood, 2017-09, Vol.130 (11), p.1375-1377</ispartof><rights>2017 American Society of Hematology</rights><rights>2017 by The American Society of Hematology 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c463t-b8cfc34287071b560ed781c039b0bfa0ab3e30ca2a672bd2e1049e83aea42a913</citedby><cites>FETCH-LOGICAL-c463t-b8cfc34287071b560ed781c039b0bfa0ab3e30ca2a672bd2e1049e83aea42a913</cites><orcidid>0000-0001-7710-7293 ; 0000-0002-1361-7531</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28733323$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Connors, Joseph M.</creatorcontrib><creatorcontrib>Ansell, Stephen M.</creatorcontrib><creatorcontrib>Fanale, Michelle</creatorcontrib><creatorcontrib>Park, Steven I.</creatorcontrib><creatorcontrib>Younes, Anas</creatorcontrib><title>Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma</title><title>Blood</title><addtitle>Blood</addtitle><description>Publisher's Note:
There is an
Inside
Blood
Commentary
on this article in this issue.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Antineoplastic Agents, Immunological - administration & dosage</subject><subject>Antineoplastic Agents, Immunological - adverse effects</subject><subject>Antineoplastic Agents, Immunological - pharmacology</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Bleomycin - administration & dosage</subject><subject>Bleomycin - adverse effects</subject><subject>Brentuximab Vedotin</subject><subject>Dacarbazine - administration & dosage</subject><subject>Disease-Free Survival</subject><subject>Doxorubicin - administration & dosage</subject><subject>Drug Interactions</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Hodgkin Disease - drug therapy</subject><subject>Humans</subject><subject>Immunoconjugates - administration & dosage</subject><subject>Immunoconjugates - adverse effects</subject><subject>Immunoconjugates - pharmacology</subject><subject>Kaplan-Meier Estimate</subject><subject>Letter to</subject><subject>Lung Diseases - chemically induced</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Molecular Targeted Therapy</subject><subject>Remission Induction</subject><subject>Treatment Outcome</subject><subject>Vinblastine - administration & dosage</subject><subject>Young Adult</subject><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UU1v1DAUtBCILoV_gJCPXAzPdhJnL0hLSylSJS7A1fLHy64hiRc7Sdl_j5ctBS6c5vDezHszQ8hzDq84b8Vr28fomQCuGNRMtVWj2gdkxWvRMgABD8kKABpWrRU_I09y_grAKynqx-RMtEpKKeSKpKuwIDugSbSLfR9v2bynsaM24TjNP8JgLF3QxymM1MXBhhE9vQ3Tjm7efrmkMdFNga6g8YsZHXqWJ7NF6nqTc3Cmp9fRb78Ven8Y9rs4mKfkUWf6jM_u8Jx8vnr36eKa3Xx8_-Fic8Nc1ciJ2dZ1TlblVVDc1g2gVy13INcWbGfAWIkSnBGmUcJ6gRyqNbbSoKmEWXN5Tt6cdPezHdC7YiiZXu9TMZUOOpqg_52MYae3cdG1apq2kkXg5Z1Ait9nzJMeQnbY92bEOGfN10LU0NaqLqvVadWlmHPC7v4MB32sS_-qSx_r0lDrU12F9uLvF-9Jv_v54wFLUEvApLMLeIw5JHST9jH8_8JPZY2pKA</recordid><startdate>20170914</startdate><enddate>20170914</enddate><creator>Connors, Joseph M.</creator><creator>Ansell, Stephen M.</creator><creator>Fanale, Michelle</creator><creator>Park, Steven I.</creator><creator>Younes, Anas</creator><general>Elsevier Inc</general><general>American Society of Hematology</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-7710-7293</orcidid><orcidid>https://orcid.org/0000-0002-1361-7531</orcidid></search><sort><creationdate>20170914</creationdate><title>Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma</title><author>Connors, Joseph M. ; Ansell, Stephen M. ; Fanale, Michelle ; Park, Steven I. ; Younes, Anas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c463t-b8cfc34287071b560ed781c039b0bfa0ab3e30ca2a672bd2e1049e83aea42a913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Antineoplastic Agents, Immunological - administration & dosage</topic><topic>Antineoplastic Agents, Immunological - adverse effects</topic><topic>Antineoplastic Agents, Immunological - pharmacology</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Bleomycin - administration & dosage</topic><topic>Bleomycin - adverse effects</topic><topic>Brentuximab Vedotin</topic><topic>Dacarbazine - administration & dosage</topic><topic>Disease-Free Survival</topic><topic>Doxorubicin - administration & dosage</topic><topic>Drug Interactions</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Hodgkin Disease - drug therapy</topic><topic>Humans</topic><topic>Immunoconjugates - administration & dosage</topic><topic>Immunoconjugates - adverse effects</topic><topic>Immunoconjugates - pharmacology</topic><topic>Kaplan-Meier Estimate</topic><topic>Letter to</topic><topic>Lung Diseases - chemically induced</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Molecular Targeted Therapy</topic><topic>Remission Induction</topic><topic>Treatment Outcome</topic><topic>Vinblastine - administration & dosage</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Connors, Joseph M.</creatorcontrib><creatorcontrib>Ansell, Stephen M.</creatorcontrib><creatorcontrib>Fanale, Michelle</creatorcontrib><creatorcontrib>Park, Steven I.</creatorcontrib><creatorcontrib>Younes, Anas</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Connors, Joseph M.</au><au>Ansell, Stephen M.</au><au>Fanale, Michelle</au><au>Park, Steven I.</au><au>Younes, Anas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma</atitle><jtitle>Blood</jtitle><addtitle>Blood</addtitle><date>2017-09-14</date><risdate>2017</risdate><volume>130</volume><issue>11</issue><spage>1375</spage><epage>1377</epage><pages>1375-1377</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><abstract>Publisher's Note:
There is an
Inside
Blood
Commentary
on this article in this issue.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>28733323</pmid><doi>10.1182/blood-2017-05-784678</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0001-7710-7293</orcidid><orcidid>https://orcid.org/0000-0002-1361-7531</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0006-4971 |
| ispartof | Blood, 2017-09, Vol.130 (11), p.1375-1377 |
| issn | 0006-4971 1528-0020 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5766843 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Adolescent Adult Antineoplastic Agents, Immunological - administration & dosage Antineoplastic Agents, Immunological - adverse effects Antineoplastic Agents, Immunological - pharmacology Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bleomycin - administration & dosage Bleomycin - adverse effects Brentuximab Vedotin Dacarbazine - administration & dosage Disease-Free Survival Doxorubicin - administration & dosage Drug Interactions Female Follow-Up Studies Hodgkin Disease - drug therapy Humans Immunoconjugates - administration & dosage Immunoconjugates - adverse effects Immunoconjugates - pharmacology Kaplan-Meier Estimate Letter to Lung Diseases - chemically induced Male Middle Aged Molecular Targeted Therapy Remission Induction Treatment Outcome Vinblastine - administration & dosage Young Adult |
| title | Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T11%3A58%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Five-year%20follow-up%20of%20brentuximab%20vedotin%20combined%20with%20ABVD%20or%20AVD%20for%20advanced-stage%20classical%20Hodgkin%20lymphoma&rft.jtitle=Blood&rft.au=Connors,%20Joseph%20M.&rft.date=2017-09-14&rft.volume=130&rft.issue=11&rft.spage=1375&rft.epage=1377&rft.pages=1375-1377&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood-2017-05-784678&rft_dat=%3Cproquest_pubme%3E1922508575%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1922508575&rft_id=info:pmid/28733323&rft_els_id=S0006497120328779&rfr_iscdi=true |